Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study

Fig. 2

Relationship of 2-h Pain Freedom to Change in HIT-6 and Occurrence of Subsequent Migraine. A Mean Change From Baseline to Week 4 in HIT-6 Total Score and B Percent of Patients Without a New Migraine Occurring With or Without Headache Pain Freedom at 2 Hours After Infusion Start. CI, confidence interval; HIT-6, 6-item Headache Impact Test; LS, least square. aLimited to patients with both baseline and post-baseline HIT-6 data

Error bars represent 95% CI

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us